Preliminary studies suggest that glucagon-like peptide-1 receptor (GLP-1) agonists, used to treat type 2 diabetes and obesity, may decrease alcohol consumption. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.